Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Fineline Cube May 12, 2026
Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026
Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026
Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Fineline Cube May 13, 2026
Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Fineline Cube May 13, 2026
Company

Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus

Fineline Cube Aug 31, 2023

China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first...

Policy / Regulatory

CDE Releases 73rd Batch of Chemical Generic Reference Preparations with Updates

Fineline Cube Aug 31, 2023

The Center for Drug Evaluation (CDE) has released the 73rd batch of chemical generic reference...

Company

Lee’s Pharmaceutical Holdings Ltd Reports H1 2023 Revenue Dip Amid Product Portfolio Growth

Fineline Cube Aug 31, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its financial report for the first...

Company Deals

Watchmaker Genomics and Exact Sciences Corporation Ink Deal to Advance TAPS Technology

Fineline Cube Aug 31, 2023

US-based Watchmaker Genomics has announced a multi-year, co-exclusive agreement with compatriot firm Exact Sciences Corporation...

Company Deals

XtalPi Inc. Partners with Edelweiss Connect to Revolutionize Skincare Safety Assessment

Fineline Cube Aug 31, 2023

Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership with...

Company Deals

Takeda Secures Exclusive Rights to ImmunoGen’s Elahere in Japan Through New Agreement

Fineline Cube Aug 31, 2023

Japanese pharmaceutical company Takeda (TYO: 4502) has entered into an exclusive collaboration and license agreement...

Company

Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff

Fineline Cube Aug 31, 2023

Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for...

Company

Zhejiang Dian Diagnostics Reports 2023H1 Revenue Dip, Strategic Expansion Continues

Fineline Cube Aug 31, 2023

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has released its financial report for the...

Company Deals

Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development

Fineline Cube Aug 31, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech,...

Company Drug

Pfizer and BioNTech Receive Positive CHMP Opinion for Comirnaty Vaccine

Fineline Cube Aug 31, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Dizal Pharmaceutical’s Golidocitinib Earns Priority Review for r/r PTCL Treatment in China

Fineline Cube Aug 30, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its drug golidocitinib has been...

Company Deals

Ronovo Surgical Secures Pre-Series B+ Funding to Advance Modular Surgical Robots

Fineline Cube Aug 30, 2023

Shanghai-based minimally invasive surgical robot developer, Ronovo Surgical, has reportedly raised close to RMB 200...

Company Drug

AIM Vaccine Co., Ltd Launches Phase III Trial for 23-Valent Pneumococcal Vaccine

Fineline Cube Aug 30, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the commencement of a Phase III...

Company Deals

Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies

Fineline Cube Aug 30, 2023

Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million)...

Company Deals

Epigenic Therapeutics Secures $32 Million in Series A Funding for Gene Modulation Therapy

Fineline Cube Aug 30, 2023

Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has...

Company Deals

Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies

Fineline Cube Aug 30, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced...

Company Drug

CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval

Fineline Cube Aug 30, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...

Company Drug

Jiangsu Yahong Meditech Gets NMPA Approval for APL1401 Ulcerative Colitis Trial

Fineline Cube Aug 30, 2023

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer based in...

Company

Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales

Fineline Cube Aug 30, 2023

China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half...

Company

Fosun Pharma Reports Moderate Revenue Growth and Increased R&D Spend in 2023 Interim Report

Fineline Cube Aug 30, 2023

Fosun Pharma (SHA: 600196) has released its 2023 interim financial report, recording revenues of RMB...

Posts pagination

1 … 479 480 481 … 664

Recent updates

  • ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform
  • Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition
  • Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal
  • Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection
  • Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Others

Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Company Medical Device

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.